Cudetaxestat
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cudetaxestat
- DrugBank Accession Number
- DB18203
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 482.33
Monoisotopic: 481.0230096 - Chemical Formula
- C21H15Cl2F2N3O2S
- Synonyms
- 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1h-pyrazol-4-yl)-1h-indol-3-yl)thio)-2-fluorobenzoic acid
- Benzoic acid, 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1h-pyrazol-4-yl)-1h-indol-3-yl)thio)-2-fluoro-
- BLD-0409
- Cudetaxestat
- External IDs
- BLD-0409
- BLD0409
- PAT-409
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cudetaxestat sodium 6FZL38CMV9 2051449-64-8 SQXRDXQCMONZTH-UHFFFAOYSA-M
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6B7TYB2MJX
- CAS number
- 1782070-21-6
- InChI Key
- NMDFAQXLJQRHMS-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H15Cl2F2N3O2S/c1-2-8-27-10-11(9-26-27)28-18-13(6-7-14(22)17(18)25)19(20(28)23)31-15-5-3-4-12(16(15)24)21(29)30/h3-7,9-10H,2,8H2,1H3,(H,29,30)
- IUPAC Name
- 3-{[2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl]sulfanyl}-2-fluorobenzoic acid
- SMILES
- CCCN1C=C(C=N1)N1C(Cl)=C(SC2=CC=CC(C(O)=O)=C2F)C2=CC=C(Cl)C(F)=C12
References
- General References
- Not Available
- External Links
- ChemSpider
- 115007997
- ChEMBL
- CHEMBL4802146
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Not Yet Recruiting Treatment Idiopathic Pulmonary Fibrosis (IPF) 1 1 Completed Other Drug Drug Interaction (DDI) 1 1 Completed Treatment Chronic Liver Disease / Non-Alcoholic Steatohepatitis (NASH) 1 1 Completed Treatment Drug Drug Interaction (DDI) 1 1 Completed Treatment Relative Bioavailability 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 6.21 Chemaxon pKa (Strongest Acidic) 3.18 Chemaxon pKa (Strongest Basic) 1.31 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.05 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 140.3 m3·mol-1 Chemaxon Polarizability 45.91 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 13, 2023 20:00 / Updated at September 28, 2023 05:48